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ABSTRACT Gout represents a metabolic disorder with systemic 
echo, in which needle-like crystals of monosodium urate are de-
posited in various tissular structures. Crystals accumulation in the 
connective tissue (tophi) represents the late, chronic stage of this 
disease, usually emerging after an average of 10 years after disease 
onset. Herein we report three cases of patients aged 70, 33, and 53 
who presented with painful subcutaneous nodules located on var-
ious body areas. All of them had hyperuricemia. Several conditions 
had to be investigated in order to establish the etiology of uric acid 
metabolism alterations. Laboratory and pathology findings estab-
lished the diagnosis of gout, with tophi as the first symptom of the 
disease. Following patient education, diet and lifestyle changes, 
and medication, the outcome in all patients was favorable, with al-
leviation of the symptoms. Tophaceous gout as a first presentation 
of this disease is currently uncommon, but dermatologist should 
be aware of this rare finding for proper management of such cases 
and to prevent the resultant significant functional and quality of 
life impairment if not recognized early.
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INTRODUCTION
Gout, a clinical syndrome caused by a group of 
heterogeneous conditions, with potential systemic 
echo, is characterized by deposition of monosodium 
urate crystals in various tissues – first the bone and 
articular tissues, followed by soft tissues or the renal 
tract. it represents the most common type of inflam-
matory arthritis affecting elderly people, especially 
men over 40 years of age (1), and has a general es-
timated prevalence of 1-4% (2). Usually, the evolu-
tion of gout corresponds to four stages in the clinical 
picture: asymptomatic hyperuricemia, acute gouty 
arthritis, intercritical gout, and chronic tophaceous 
gout (3). Chronic tophaceous gout represents the 
late stage of this metabolic disorder, which normally 
develops after prolonged disease evolution following 
multiple years of recurrent gout attacks, usually in un-
treated or partly treated patients (4), more frequently 
in women (27%) compared with men (10%) (5). 
Tophaceous gout as the first manifestation of 
gout with no previous gout attacks represents an 
uncommon presentation of this disease, with 96 
cases described in the literature between 1970 and 
2017, which were associated with certain risk factors 
such as increased age, female gender, chronic kid-
ney disease, and diuretic treatment (4). Furthermore, 
it has been shown that tophi development without 
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previous gout attacks are also associated with lower 
serum levels of uric acid, compared with patients who 
develop tophi after many years of recurrent gouty at-
tacks (6). Due to recent and continuous shifts regard-
ing diet (increased fast food intake), lifestyle (lack of 
physical exercises associated with increased rates of 
sedentariness, increased incidence of obesity and 
metabolic syndrome) (2), medical care, and enhanced 
longevity, an increased prevalence of gout in general 
and chronic tophaceous gout in particular has been 
recorded worldwide (4); this represents an indicator 
of a need for an improved effort towards early identi-
fication of patients with gout as well as their disease 
process (7).
we present three cases of tophaceous gout as the 
first clinical presentation without previous gout at-
tacks, in male patients aged 70, 33, and 53 years old, 
without any significant medical or drug intake history 




A 70-year-old man presented with multiple pain-
ful erythematous nodules 5-15 mm in diameter lo-
cated on the palmar and dorsal aspects of the fingers 
(Figure 1, a, b), which had been evolving for six weeks 
and were associated with impairment of daily activi-
ties. Many of these nodules were ulcerated, occasion-
ally expressing a dense, white-chalky material. Signif-
icant dysfunction of the adjacent joints was present. 
The patient had no other conditions mentioned in his 
medical record and denied alcohol abuse.
Laboratory investigations revealed a moderate in-
flammatory syndrome and elevated levels of serum 
uric acid. The patient denied receiving treatment with 
diuretics or any other drugs that could be incriminat-
ed in increasing uric acid levels.
A biopsy of one of the nodules was performed, 
with the pathology report revealing granulomatous 
inflammation surrounding needle-like spaces in a 
radial arrangement, representing crystals dissolved 
during processing (Figure 1, c, d).
The pathology report, taken together with clini-
cal and laboratory data, supported the diagnosis of 
tophaceous gout.
Therapy with non-steroidal anti-inflammatory 
drugs (NSAiDs) and allopurinol was initiated (8), with 
a favorable evolution during treatment and gradual 
decreasing of the inflammation and associated pain 
(Table 1).
Case 2
A 33-year-old man was referred to our clinic for 
multiple painful erythematous nodules, with the big-
gest (35/20 mm) located on the dorsal aspect of the 
third metacarpophalangeal joint of the right hand 
(Figure 2, a). Other smaller nodules were present on 
helix of the left ear, the left elbow, the extension area 
of the left forearm (Figure 2, b), and the second digit 
of the left foot (Figure 2, d). The nodules had been 
growing over the past four years, and a week before 
hospital admission the patient experienced an epi-
sode of painful erythema and edema of the metacar-
pophalangeal joints of the left hand, with improve-
ment of the symptoms after NSAiDs treatment. The 
Figure 1. erythematous nodules on the palmar (a) and dor-
sal aspects (b) of the fingers; (c), (d) pathological aspects: 
granulomatous inflammation surrounding needle-like 
spaces in a radial arrangement, representing crystals dis-
solved during processing (c: hematoxylin-eosin stain, ×20; 
d: hematoxylin-eosin stain, ×40).
Figure 2. Multiple painful erythematous nodules 5-35 mm 
in diameter on the dorsal aspect of the third metacarpo-
phalangeal joint (a) and the left elbow (b); hands X-ray re-
vealing demineralization in both radio-carpal joints, proxi-
mal inter-phalangeal joints arthritis of left hand digits ii-V 
(c); painful nodule on the second digit of the left foot (d).
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patient denied smoking, alcohol consumption, other 
medical conditions, or any medication usage before 
admission.
Laboratory investigations revealed a moderate 
inflammatory syndrome, elevated uric acid levels, 
hypercholesterolemia, and hypertriglyceridemia. X-
ray of the hands identified demineralization in both 
radio-carpal joints (predominantly on the left hand) 
and proximal interphalangeal joints arthritis of the 
left ii-V digits in the hand (Figure 2, c).
The clinical picture was highly suggestive of to-
phaceous gout, and NSAiDs and allopurinol therapy 
was started, with favorable evolution of the patient 
(Table 1).
Case 3
A 53-year-old man presented with white-yellow-
ish, sharply demarcated, asymptomatic nodules, 7-13 
mm in diameter, firm on palpation, located on the 
helix and antehelix regions of both ears (Figure 3, a, 
b), that had been evolving for two years, with an in-
crease of their count in the last six months.
The patient was hypertensive are was receiving 
treatment with beta blockers. He denied alcohol 
abuse. 
Laboratory test revealed a moderate inflamma-
tory syndrome, high levels of uric acid, and hepatic 
cytolysis. 
The nodules were excised and a biopsy was per-
formed, with the pathology report showing granulo-
matous inflammation surrounding needle-like spaces 
in a radial arrangement and negatively bi-refringent 
needle-like crystals by polarized microscopy.
Combining the pathology report with clinical pic-
ture and laboratory data, the diagnosis of tophaceous 
gout was established.
Under allopurinol treatment, the patient’s evolu-
tion was favorable (Figure 3, c, d), with good general 
condition, no joint pain, and no new cutaneous le-
sions observed at one-year follow-up visit (Table 1).
Figure 3. Multiple white-yellowish nodules, 7-13 mm in di-
ameter, sharply demarcated, asymptomatic, firm to palpa-
tion, located on the helix and antehelix regions of the left 
ear (a) and right ear (b); favorable evolution under allopuri-
nol treatment on left ear (c) and right ear (d).
Table 1. Clinical details of the three patients with tophaceous gout
Characteristic Patient 1 Patient 2 Patient 3
Sex M M M
Age (years) 70 33 53
Preceding history of 
gout
None Cutaneous nodules for four years
No arthritis/arthralgia
Cutaneous nodules for two 
years












None None Hypertension (beta blockers 
treatment)
Localization of the 
tophi
Fingers Right hand, left ear helix, left 
elbow, left forearm
ears
Follow-up (one year) No lesions No lesions No lesions
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DISCUSSION
Gout develops as a consequence of purine metab-
olism abnormalities in which urate crystals precipitate 
from body fluids and form tissular deposits, including 
cutaneous ones – tophi (3). elevated plasma levels of 
uric acid represent a risk factor for the development 
of gout, but tophaceous gout without previous recur-
rent flares of gouty arthritis is associated with lower 
levels of serum uric acid (6). Hyperuricemia can be 
primary (due to a genetic enzymatic defect of the pu-
rine metabolism) or secondary, with multiple causes: 
renal excretion impairment, drug-induced, alcohol 
abuse, excessive dietary intake of purines, and in-
creased turnover of nucleic acids (myeloproliferative 
or lymphoproliferative disorders, hemolytic anemia). 
The most frequently incriminated drugs in the devel-
opment of hyperuricemia are diuretics, cyclosporine 
and salicylates (1).
in general, tophi develop after an average of ten 
years after the onset of gout and usually in patients 
with previous uncontrolled gout (4). However, in un-
usual cases they can represent the first manifestation 
of the disease. Calcium pyrophosphate dehydrate 
crystal deposits in pseudogout (chondrocalcinosis), 
xanthomas, and rheumatoid nodules can be con-
fused with gouty tophi, but histopathologic examina-
tion helps to confirm the diagnosis of gout.
Tophaceous gout is currently considered uncom-
mon, and its presentation should elicit an investi-
gation for various causes of hyperuricemia (9), (10). 
Purine enzyme defects are rare both in young and 
elderly patients. Genetic testing was not performed 
in our patients; secondary causes of hyperuricemia 
were taken into account. Renal failure, acidosis, and 
increased nucleotide turn-over were excluded by 
laboratory tests, and alcohol abuse or potential gout-
precipitating medication administration was denied 
by all three patients. Therefore, it was necessary to 
investigate other rare conditions involving hyper-
uricemia, like hypothyroidism, hyperthyroidism, and 
hypoparathyroidism, which was achieved by testing 
for serum calcium levels and TSH – found to be within 
normal limits. Accordingly, it was concluded that ex-
cessive dietary purines were the cause of tophaceous 
gout development in our patients.
Chronic tophaceous gout, if not managed proper-
ly, is associated with important functional and quality 
of life impairment (11), eventually leading to signifi-
cant erosive bone disease and notable joint damage 
(12), which may prove to be significantly debilitating.
The cases presented in this paper present some 
unique aspects. Firstly, all patients presented imme-
diately with tophaceous gout as the first manifesta-
tion of the disease, without any prior history of recur-
rent gouty arthritis, given that tophi develop in the 
last stage of poorly controlled gout (3). Secondly, all 
patients were men and, although gout is more fre-
quently encountered in male patients, tophaceous 
gout is found more frequently among female pa-
tients (4). Furthermore, although it is well-known that 
tophaceous gout without previous gouty flares is en-
countered especially commonly in the elderly popu-
lation (6), two of the patients we presented were of 
33 and 53 years old. Lastly, one of the patients pre-
sented with multiple ulcerated tophi, ulceration be-
ing quite uncommon in such lesions (13).
CONCLUSION
Although it is the rule of the natural progression of 
gout for the cutaneous tissue to be affected after the 
joints have been previously affected, in clinical prac-
tice patients might present with skin involvement 
in the shape of tophi as the first sign of this disease. 
Furthermore, even if, patients with gout are started 
on the appropriate treatment and therefore they do 
no develop tophi in the modern era of medicine, in 
daily practice, medical doctors may encounter cases 
of tophaceous gout as a result of either a longstand-
ing unknown and uncontrolled gout or as a first clini-
cal manifestation. Therefore, this clinical article high-
lights the necessity of dermatologists being aware of 
this uncommon first manifestation of gout in estab-
lishing an early diagnosis and proper management 
of such cases, leading to a decrease in the significant 
debilitating potential of this disease.
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